公开(公告)号：US20170152488A1

公开(公告)日：2017-06-01

申请号：US15309690

申请日：2014-08-04

申请人： ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. ,  ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD. ,  TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. ,  ASYMCHEM LABORATORIES (FUXIN) CO., LTD. ,  JILIN ASYMCHEM LABORATORIES CO., LTD.

发明人： Hao Hong ,  James Gage ,  Feng Gao ,  Lihui Liu ,  Wenyan Yu ,  Fang Liu ,  Lina Guo ,  Na Zhang

IPC分类号： C12N9/04 ,  C12P7/62

CPC分类号： C12N9/0006 ,  C12N5/10 ,  C12N15/63 ,  C12P7/62 ,  C12Y101/01184

摘要： The application provides a Diketoreductase (DKR) mutant, its nucleotide coding sequence, and an expression cassette, recombinant vector and host cell containing the sequence, as well as a method for application of the mutant to the preparation of 3R,5S-dicarbonyl compound. An ee value of the obtained 3R,5S-dicarbonyl compound is higher than 99%, and a de value is about 90%. The DKR mutant is a key pharmaceutical intermediate, and particularly provides an efficient catalyst for synthesis of a chiral dicarbonyl hexanoic acid chain of a statin drug.

公开(公告)号：US20170002338A1

公开(公告)日：2017-01-05

申请号：US15039736

申请日：2014-10-29

申请人： ASYMCHEM LABORATORIES (TIANJIN) CO., LTD ,  ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD ,  TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD ,  ASYMCHEM LABORATORIES (FUXIN) CO., LTD ,  JILIN ASYMCHEM LABORATORIES CO., LTD

发明人： Hao HONG ,  Feng GAO ,  Yanjun LI ,  Yan ZHANG ,  Shaohe LI

IPC分类号： C12N9/10 ,  C12P13/00 ,  C12P17/12

CPC分类号： C12N9/1096 ,  C12P13/001 ,  C12P17/12 ,  C12P41/006 ,  C12Y206/01

摘要： An omega-transaminase of R-configuration is provided. The omega-transaminase of R-configuration has the amino acid sequence as shown in SEQ ID NO: 2, or has at least 80% identity to the amino acid sequence as shown in SEQ ID NO: 2, or has the amino acid sequence of proteins which have substituted, deleted or added one or more amino acids and have the activity of an omega-transaminase with a high stereoselectivity R-configuration catalytic activity; and does not have the amino acid sequence encoded by the nucleotide sequence as shown in SEQ ID NO: 4. The high stereoselectivity refers to the content of one of the stereoisomers being at least about 1.1 times that of the other. A use of the omega-transaminase of R-configuration is provided.

摘要翻译： 提供R-构型的ω-转氨酶。 R构型的ω-转氨酶具有如SEQ ID NO：2所示的氨基酸序列，或与SEQ ID NO：2所示的氨基酸序列具有至少80％的同一性，或具有SEQ ID NO：2所示的氨基酸序列 具有取代，缺失或添加一个或多个氨基酸并且具有高立体选择性R构型催化活性的ω-转氨酶活性的蛋白质; 并且不具有由SEQ ID NO：4所示的核苷酸序列编码的氨基酸序列。高立体选择性是指立体异构体之一的含量为至少约1.1倍。 提供了R-构型的ω-转氨酶的用途。

公开(公告)号：US20160319312A1

公开(公告)日：2016-11-03

申请号：US14783653

申请日：2013-07-29

申请人： ASYMCHEM LABORATORIES (TIANJIN) CO., LTD ,  ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD ,  TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD ,  ASYMCHEM LABORATORIES (FUXIN) CO., LTD ,  JILIN ASYMCHEM LABORATORIES CO., LTD.

发明人： Hao Hong ,  Changsheng Zheng ,  Lina Guo

IPC分类号： C12P13/00 ,  A61K31/351 ,  A61K31/198

CPC分类号： C12P13/005 ,  A61K31/198 ,  A61K31/351 ,  C12P13/04 ,  C12Y104/01009

摘要： A synthesis method for L-cyclic alkyl amino acid and a pharmaceutical composition having the said amino acid are provide in the present disclosure provides. The synthesis method comprises: step A.) preparing a cyclic alkyl keto acid or a cyclic alkyl keto acid salt having Structural Formula (I) or Structural Formula (II), and step B.) mixing the cyclic alkyl keto acid or the cyclic alkyl keto acid salt with ammonium formate, a leucine dehydrogenase, a formate dehydrogenase and a coenzyme NAD+, and carrying out a reductive amination reaction to generate the L-cyclic alkyl amino acid, wherein the Structural Formula (I) is where n1≧1, m1≧0 and the M1 is H or a monovalent cation; the Structural Formula (II) is where n2≧0, m2≧0, the M2 is H or a monovalent cation, an amino acid sequence of the leucine dehydrogenase is SEQ ID No.1.

摘要翻译： 其中n2≥0，m2≥0，M2是H或一价阳离子，亮氨酸脱氢酶的氨基酸序列是SEQ ID No.1。